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Abstract
Background: Oxidized low-density lipoprotein (LDL) may act as an atheroprotective (anti-atherosclerotic) agent
under some conditions. While the a1-antitrypsin (AT)-LDL complex is considered a type of oxidized LDL, its clinical
relevance remains unknown. The aim of the present study was to investigate the association between AT-LDL and
anti-atherosclerotic variables such as HDL-cholesterol and adiponectin in subjects with and without metabolic
syndrome (MetS).
Methods: In asymptomatic females (n = 194; mean age, 54 years) who were divided into non-MetS (n = 108) and
MetS groups (n = 86), the fasting levels of serum AT-LDL, adiponectin and glucose/lipid panels were measured, in
addition to body mass index (BMI) and blood pressure.
Results: The MetS group showed significantly higher BMI, blood pressure, glucose and triglyceride levels as well as
significantly lower levels of HDL-cholesterol and adiponectin than the non-MetS group. A multivariate-adjusted
analysis revealed that in the non-MetS group, AT-LDL was significantly, independently and positively correlated
with adiponectin (b = 0.297, P < 0.05), along with HDL-cholesterol (b = 0.217, P < 0.05). In the MetS group, AT-LDL
was significantly, independently and positively correlated with LDL-cholesterol only (b = 0.342, P < 0.05).
Conclusions: These data suggest that AT-LDL may exert anti-atherosclerotic effects in female subjects without
MetS. More studies are required to clarify the clinical roles of AT-LDL in relation to the pathophysiology of MetS.
Background
Atherosclerosis is an important health concern, because
it leads to cardiovascular disease [1]. Oxidation of
low-density lipoprotein (LDL) is involved in the athero-
sclerotic processes, and oxidized LDL (oxLDL) can
exhibit atherogenic properties [2,3]. Recent research has
shown that various types of oxLDL exist both in athero-
sclerotic lesions and in the circulation, and the circulat-
ing oxLDL is presently thought to be a useful marker
reflecting one’s atherosclerotic state [4-6]. On the other
hand, it is becoming increasingly clear that oxLDL
exerts dual effects on atherosclerosis [7-15]. Namely,
low levels (small amounts) of oxLDL can exert an ather-
oprotective (anti-atherosclerotic) effect. However, the
clinical data about this phenomenon are limited, and
more clinical investigations are needed.
While a1-antitrypsin (AT), a serine-proteinase inhibi-
tor, protects tissues from damage caused by excess
activities of proteinases [16], when AT is oxidized, it
loses its inhibitory activity and activates monocytes [17].
Oxidized AT has been shown to form a complex with
LDL in atherosclerotic lesions, and the circulating
AT-LDL complex seems to reflect the atherosclerotic
state, although the precise mechanisms underlying the
formation of the AT-LDL complex remain undeter-
mined [18]. Importantly, the clinical significance of
AT-LDL, as an oxLDL marker, in atherosclerosis is
unknown. In our previous study of a specific athero-
sclerosis-prone population with obesity and metabolic
syndrome (MetS), we did not find any significant role
for AT-LDL [19]. However, in agreement with the origi-
nal report that developed the AT-LDL measurement* Correspondence: kazukotani@jichi.ac.jp
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system [18], we have also noted that the circulating
levels of AT-LDL were very low in these patients [19].
This prompted us to investigate the association
between circulating AT-LDL and anti-atherosclerotic
variables, such as high-density lipoprotein (HDL) and
adiponectin [20]. The levels of these variables generally
differ between subjects with and without MetS (in
particular, adiponectin has recently attracted much
attention because of its association with MetS) [20].
The clinical relationship between AT-LDL and these
variables should be examined with regard to a poten-
tial role in MetS. Therefore, the aim of the present
study was to determine whether there was a correla-
tion between AT-LDL and atherosclerotic variables,
including HDL-cholesterol and adiponectin, in subjects
with and without MetS.
Subjects and Methods
A total of 194 non-medicated and asymptomatic female
participants, ranging from 35-70 years of age, were
recruited during routine check-ups in the health educa-
tion classes and outpatient clinics. The study population
was composed of subjects without MetS (n = 108) and
with MetS (n = 86) (Table 1). The eligible subjects had
no histories of cardiovascular, thyroid, hematological,
kidney or liver diseases. The existence of 3 out of 5 of
the following criteria constituted a diagnosis of MetS
according to the National Cholesterol Education Pro-
gram Adult Treatment Panel (NCEP-ATP) III recom-
mendations [21]: 1) obesity identified by a body mass
index (BMI) ≥ 25.0 kg/m2 as a surrogate for Japanese
subjects [22], 2) elevated blood pressure (BP) identified
by systolic BP (SBP) ≥ 130 mmHg and/or diastolic BP
(DBP) ≥ 85 mmHg, 3) hypertriglyceridemia identified by
serum triglyceride (TG) ≥ 1.69 mmol/L, 4) decreased
HDL-cholesterol identified by serum HDL-cholesterol
<1.29 mmol/L, and 5) elevated glucose status identified
by a fasting plasma glucose (FPG) ≥ 6.1 mmol/L. The
study was approved by the Jichi Medical University
ethics committee, and all subjects gave their informed
consent.
Current smoking was defined as the presence of cur-
rent smoking habits via a self-report and professional
interview. In addition to the BMI, the SBP and DBP
levels were determined in the seated subject’s right-arm
with a mercury sphygmomanometer after 5 minutes of
rest. During an overnight fast, the serum TG and FPG
levels were measured using enzymatic methods, and the
serum LDL-cholesterol and HDL-cholesterol levels were
measured using homogeneous methods. The serum adi-
ponectin levels were measured with an enzyme-linked
immunosorbent assay (Otsuka Pharmaceutical Co. Ltd.,
Tokyo, Japan). Serum AT-LDL levels were determined
according to an enzyme-linked immunosorbent assay
method, as described previously [18,19]. Briefly, fresh
serum samples (50 L/well) were incubated overnight at
4°C with the anti-human AT-specific antibody (DAKO
Denmark A/S, Glostrup, Denmark: AT-LDL, clone
No.27) coated onto a microtiter plate. After washing, a
biotinylated Fab’ anti-human apo-B antibody was added
as the capture antibody (100 L/well), and reacted for
2 hours at room temperature. The activity was measured
in terms of the difference in optical absorbance between
450 and 620 nm after adding a peroxidase substrate,
when the reaction was terminated by adding phosphoric
acid. The intraassay coefficients of variation at low and
high concentrations of AT-LDL were 1.8% and 1.6%,
respectively. The interassay coefficients of variation at
low and high concentrations of AT-LDL were 5.9% and
5.4%, respectively. All samples were assayed in duplicate
and in random order.
The data were expressed as the means ± standard
deviation (SD) or the median plus interquartile range.
The data between the subject groups were compared
using an unpaired t-test. A simple and multivariate-
adjusted linear regression model was utilized to observe
the correlation between AT-LDL and other athero-
sclerotic variables. All of the measured variables, except
for DBP (because of its close collinearity to SBP: corre-
lation coefficient >0.6), were entered into the multivari-
ate-adjusted analysis model. The levels of TG and
adiponectin were log-transformed for all of the analyses
because of their skewed distributions. A P value ≤0.05
was considered to be statistically significant.







Age, years 54.1 ± 9.6 53.4 ± 9.5 0.618
Current smoking, % 9.3 10.5 0.779
Body mass index, kg/m2 26.0 ± 2.5 27.5 ± 1.7 <0.0001**
Systolic blood pressure,
mmHg
130 ± 17 146 ± 17 <0.0001**
Diastolic blood pressure,
mmHg
79 ± 11 87 ± 10 <0.0001**
Fasting plasma glucose,
mmol/L
5.85 ± 2.30 7.42 ± 3.10 <0.0001**
LDL-cholesterol, mmol/L 3.32 ± 0.80 3.38 ± 0.77 0.628
Triglyceride, mmol/L 1.15 (0.88-1.47) 1.88 (1.36-2.47) <0.0001**
HDL-cholesterol, mmol/L 1.71 ± 0.33 1.48 ± 0.38 <0.0001**
Adiponectin, μg/mL 8.95 (5.53-12.2) 7.80 (4.80-10.9) 0.050*
AT-LDL, μg/mL 3.27 ± 1.02 3.00 ± 0.98 0.071
MetS: metabolic syndrome, LDL: low-density lipoprotein, HDL: high-density
lipoprotein, a1-AT-LDL: a1-antitrypsin-low-density lipoprotein. Data are
expressed as the mean ± standard deviation, the median (interquartile range)
or the percentage in each subject group. Significance level (subjects without
MetS vs. those with MetS; unpaired t-test [triglyceride and adiponectin were
log-transformed] or c2 test): * P ≤ 0.05, ** P ≤ 0.01.
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Results
With regard to the clinical characteristics of the subject
groups with and without MetS (Table 1), subjects with
MetS had significantly higher BMI, SBP, DBP, FPG and
TG levels than those without MetS. The subjects with
MetS showed significantly lower levels of HDL-
cholesterol and adiponectin than those without MetS.
There were no significant differences in AT-LDL levels
between the two subject groups.
In the simple linear regression analysis (Table 2), AT-
LDL was significantly and positively correlated with
LDL-cholesterol, HDL-cholesterol and adiponectin in
the subjects without MetS. In the group with MetS, AT-
LDL was significantly and positively correlated with
LDL-cholesterol only. In a subsequent multivariate-
adjusted analysis (Table 2) in the subject group without
MetS, the AT-LDL was significantly, independently and
positively correlated with adiponectin, as well as HDL-
cholesterol. In the group with MetS, AT-LDL remained
significantly, independently and positively correlated
with LDL-cholesterol only.
Discussion
The present study is the first demonstration that
AT-LDL had a significantly positive correlation with
HDL-cholesterol and adiponectin in subjects without
MetS, but not in those with MetS. In this study, subjects
with MetS were more predisposed to be atherosclerotic,
based on their BMI, BP, glucose/lipid panels and adipo-
nectin, compared to those without MetS, which is in
agreement with previous reports [20]. In addition, the
finding of a significant correlation between AT-LDL and
LDL-cholesterol in subjects with MetS was similarly
observed in a previous study [19].
The present study provided two new findings. The
first is the atheroprotective relevance of oxLDL. Earlier
studies reported a significant inverse correlation
between adiponectin and oxLDL in patients with type 2
diabetes mellitus and coronary artery disease [23] and in
patients with chronic heart failure [24]. The significant
inverse correlation between HDL-cholesterol and oxLDL
was also reported in patients with coronary artery dis-
ease [25]. Our present results showing the significant
positive correlation between adiponectin or HDL-C and
AT-LDL would not have been expected from these
reports [23-25], although the examined populations and
oxLDL markers were different between the prior work
and our current study. However, since relatively low
levels of oxLDL can be atheroprotective [7-15], it is
important to note the possibility that AT-LDL may
exert anti-atherosclerotic effects in subjects without
MetS. This might be an important case showing an
atheroprotective aspect of oxLDL in the clinical setting.
Based on the current study alone, we cannot comple-
tely determine whether the significant relationship
between adiponectin, HDL-cholestreol and AT-LDL is a
simple (non-causative) correlation or a positive patholo-
gical link. However, we have considered the possible
biological mechanisms of such a relationship. Oxidized
LDL, as anti-atherosclerotic agent, acts through its cyto-
protection, the modulation of immunological system
and the activation of reverse cholesterol transport, as
was well-documented in Yu’s study [13]. The cytopro-
tective mechanism of oxLDL involves the regulation by
the electrophile response element, including heme
oxygenase-1 [9,26]. The atheroprotective effects of the
immunity to oxLDL are known to be induced, for
instance, by the secretion of anti-inflammatory cyto-
kines, including interleukin-10 [11,13]. There is a grow-
ing appreciation that heme oxygenase-1 plays a crucial
anti-inflammatory role in chronic inflammatory patholo-
gies induced by various factors (i.e., oxidative stress and
cytokines) and is a mediator of interleukin-10 expression
[27,28]. While adiponectin induction by oxLDL remains
Table 2 Correlations of AT-LDL with other atherosclerotic variables
Non-MetS MetS
Variable g (P value) b (P value) g (P value) b (P value)
Age, years -0.025 (0.8001) -0.127 (0.229) -0.125 (0.251) -0.197 (0.086)
Current smoking, % -0.008 (0.934) 0.033 (0.734) 0.101 (0.356) 0.116 (0.287)
Body mass index, kg/m2 -0.073 (0.452) 0.081 (0.447) -0.161 (0.138) -0.104 (0.346)
Systolic blood pressure, mmHg 0.104 (0.285) 0.008 (0.950) 0.017 (0.875) 0.104 (0.337)
Diastolic blood pressure, mmHg 0.107 (0.269) - -0.131 (0.229) -
Fasting plasma glucose, mmol/L -0.017 (0.863) 0.081 (0.413) -0.040 (0.771) 0.080 (0.464)
LDL-cholesterol, mmol/L 0.206 (0.033)* 0.144 (0.128) 0.349 (0.001)** 0.342 (0.002)**
Triglyceride, mmol/L -0.022 (0.819) 0.016 (0.860) 0.204 (0.061) 0.167 (0.120)
HDL-cholesterol, mmol/L 0.303 (0.001)** 0.217 (0.048)* -0.030 (0.784) -0.006 (0.965)
Adiponectin, μg/mL 0.330 (<0.0001)** 0.297 (0.010)** -0.041 (0.706) -0.045 (0.693)
AT-LDL: a1-antitrypsin-low-density lipoprotein, MetS: metabolic syndrome, LDL: low-density lipoprotein, HDL: high-density lipoprotein. r: simple linear regression
coefficient between a1-AT-LDL and another variable, b: multiple linear regression coefficient in a multivariate analysis for a1-AT-LDL after controlling for all the
listed variables except for diastolic blood pressure. Triglyceride and adiponectin were log-transformed for analyses. Significance level: * P ≤ 0.05, ** P ≤ 0.01.
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to be established, the key molecules (such as heme oxy-
genase-1) can show a positive association with adiponec-
tin [29]. Thus, the adiponectin/interleukin-10/heme
oxygenase-1 pathway may, at least in part, explain the
positive relationship between adiponectin and oxLDL.
Furthermore, a report demonstrating that low levels of
oxLDL increased cholesterol efflux in adipocytes has
suggested that oxLDL has an atheroprotective role by
enhancing the reverse cholesterol transport, thereby
increasing HDL-cholesterol [13,14]. This may partly
account for the positive relationship between HDL-
cholesterol and oxLDL.
The second major finding of our present study is the dif-
ferences in associations of oxLDL with anti-atherosclerotic
variables in subjects with and without MetS. The present
results showing a diminished correlation between adipo-
nectin or HDL-cholesterol and AT-LDL in subjects with
MetS are interesting, and suggest that the metabolic dysre-
gulation and homeostatic shifts specifically found in MetS
subjects (i.e., lower adiponectin or HDL-cholesterol con-
centrations [20]) may eliminate the significant link
between them found in those without MetS. Whether the
pathophysiology of MetS could specifically affect the cor-
relation pattern of atherosclerotic variables to AT-LDL
remains to be explored.
The present study had a few limitations. The cross-
sectional design did not allow for a strict cause-and-
effect conclusion to be drawn. The study was conducted
in female subjects, and we did not obtain any data on
males. There are also ethnic differences in some influ-
ences of atherosclerotic variables, including adiponectin
and cholesterol, on atherosclerotic states [30]. Therefore,
more studies with various populations and prospective
designs are called for when carrying out future studies.
Conclusions
In summary, the present study showed that AT-LDL
was significantly, independently and positively correlated
with adiponectin and HDL-cholesterol in female sub-
jects without MetS, but not in those with MetS. These
data suggest that AT-LDL may exert anti-atherosclerotic
effects in subjects without MetS. Further research is
warranted to confirm these findings and their relevance
in the clinical and basic settings.
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